Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL431554 | 1.00 | HTR2A (0.41) | HTR2AHTR2CHTR2BCA1KMT2A | |
| SCHEMBL23162031 | 1.00 | HTR2A (0.41) | HTR2AHTR2CHTR2BCA1KMT2A | |
| SCHEMBL432972 | 1.00 | HTR2A (0.41) | HTR2AHTR2CHTR2BCA1KMT2A | |
| SCHEMBL430992 | 1.00 | HTR2A (0.41) | HTR2AHTR2CHTR2BCA1KMT2A | |
| Hydrochloric Acid SCHEMBL29743634 | 0.98 | HTR2A (0.44) | HTR2AHTR2CHTR2BCA1KMT2A | |
| Hydrochloric Acid SCHEMBL23146717 | 0.98 | HTR2A (0.44) | HTR2AHTR2CHTR2BCA1KMT2A | |
| SCHEMBL18588950 | 0.82 | NOS1 (0.31) | — | |
| SCHEMBL18780631 | 0.81 | HTR2A (0.41) | HTR2AHTR2CHTR2BCA1KMT2A | |
| SCHEMBL21723161 | 0.81 | HTR2A (0.41) | HTR2AHTR2CHTR2BCA1KMT2A | |
| SCHEMBL22863023 | 0.81 | HTR2A (0.44) | HTR2AHTR2CHTR2BCA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | TNK2, CNKSR1, BMP2K | HTR2A 4025/4885HTR2C 4181/4885HTR2B 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.